0001788542-23-000006.txt : 20230721 0001788542-23-000006.hdr.sgml : 20230721 20230721174651 ACCESSION NUMBER: 0001788542-23-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230719 FILED AS OF DATE: 20230721 DATE AS OF CHANGE: 20230721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mottiwala Aziz CENTRAL INDEX KEY: 0001788542 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 231103403 MAIL ADDRESS: STREET 1: 233 WILSHIRE BOULEVARD STREET 2: SUITE 280 CITY: SANTA MONICA STATE: CA ZIP: 90401 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wk-form4_1689976000.xml FORM 4 X0508 4 2023-07-19 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001788542 Mottiwala Aziz C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 0 1 0 0 Chief Commercial Officer 1 Common Stock 2023-07-19 4 S 0 2400 20.05 D 45806 D The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 120 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023. /s/ Jeffrey Farrow, Attorney-in-Fact 2023-07-21